References
- Center for Biosimilars. Biosimilar approvals. 2023 Jul 17. [cited 2023 Aug 10]. Available from: https://www.centerforbiosimilars.com/biosimilar-approvals.
- Abraham I, Han L, Sun D, et al. Cost savings from anemia management with biosimilar epoetin α and increased access to targeted antineoplastic treatment: simulation for the European G5 countries. Future Oncol. 2014;10(9):1599–1609. doi: 10.2217/fon.14.43
- Yousef CC, Khan MA, Almodaimegh H, et al. Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study. J Med Econ. 2023;26(1):394–402. doi: 10.1080/13696998.2023.2183680
- Halawah HH, Alkhatib NS, Almutairi AR, et al. Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan. J Med Econ. 2023;26(1):835–842. doi: 10.1080/13696998.2023.2226007
- Center for Biosimilars. [cited 2023 Aug 10]. Available from: https://www.centerforbiosimilars.com/search?searchTerm=Ivo+Abraham+column.
- WHO. Guidelines on evaluation of biosimilars. [cited 2023 Aug 10]. Available from: https://www.who.int/publications/m/item/guidelines-on-evaluation-of-biosimilars.
- Calamia M, Abraham I. The economics of biosimilars: addressing the unmet medical need in low- and middle-income countries. Expert Opin Biol Ther. 2023;23(08):653–657.
- Bas TG. Biosimilars for the next decade in Latin America: a window of opportunity. Expert Opin Biol Ther. 2023;1–11. doi: 10.1080/14712598.2023.2245780
- Alkhatib NS, Haloush S, Abraham I. The status and preparation for the next decade of biosimilars in the middle Eastern and North African region. Expert Opin Biol Ther. 2023;1–7. doi: 10.1080/14712598.2023.2241346
- Almutairi AR, Al-Samil AM, Alsayyari A, et al. The landscape of biosimilars in Saudi Arabia: preparing for the next decade. Expert Opin Biol Ther. 2023;1–10.
- Sharma A, Kumar N, Parachuri N, et al. Preparing for the next decade of anti-VEGF biosimilars for retinal diseases: a focus on South Asia. Expert Opin Biol Ther. 2023;1–4.
- Joshi SR, Mittra S, Raj P, et al. Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective. Expert Opin Biol Ther. 2022;1–12.